Bokf Na Purchases 29,846 Shares of Innoviva, Inc. (NASDAQ:INVA)

BOKF NA increased its stake in shares of Innoviva, Inc. (NASDAQ:INVA - Free Report) by 180.5% in the second quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 46,377 shares of the biotechnology company's stock after acquiring an additional 29,846 shares during the quarter. BOKF NA owned about 0.07% of Innoviva worth $761,000 at the end of the most recent quarter.

Several other institutional investors also recently bought and sold shares of the stock. Texas Permanent School Fund Corp lifted its position in Innoviva by 1.4% during the first quarter. Texas Permanent School Fund Corp now owns 49,358 shares of the biotechnology company's stock valued at $752,000 after purchasing an additional 662 shares during the last quarter. ProShare Advisors LLC raised its position in Innoviva by 6.2% in the 1st quarter. ProShare Advisors LLC now owns 16,150 shares of the biotechnology company's stock worth $246,000 after purchasing an additional 942 shares during the period. SummerHaven Investment Management LLC raised its position in Innoviva by 1.7% in the 2nd quarter. SummerHaven Investment Management LLC now owns 59,853 shares of the biotechnology company's stock worth $982,000 after purchasing an additional 980 shares during the period. Quadrant Capital Group LLC lifted its stake in Innoviva by 13.2% in the fourth quarter. Quadrant Capital Group LLC now owns 9,042 shares of the biotechnology company's stock worth $145,000 after purchasing an additional 1,056 shares during the last quarter. Finally, Principal Financial Group Inc. boosted its position in shares of Innoviva by 0.3% during the first quarter. Principal Financial Group Inc. now owns 323,991 shares of the biotechnology company's stock valued at $4,938,000 after buying an additional 1,121 shares during the period. 99.12% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

A number of research analysts have recently commented on INVA shares. Cantor Fitzgerald reaffirmed an "overweight" rating on shares of Innoviva in a research note on Tuesday, July 30th. StockNews.com cut Innoviva from a "strong-buy" rating to a "buy" rating in a research note on Tuesday, August 6th.

Innoviva Trading Up 0.9 %

Shares of INVA traded up $0.18 during mid-day trading on Monday, reaching $19.99. 231,961 shares of the company's stock traded hands, compared to its average volume of 580,603. The stock has a market cap of $1.25 billion, a P/E ratio of 9.04 and a beta of 0.57. The stock's 50-day moving average is $18.41 and its two-hundred day moving average is $16.49. Innoviva, Inc. has a 12 month low of $12.22 and a 12 month high of $20.19. The company has a debt-to-equity ratio of 0.67, a current ratio of 12.70 and a quick ratio of 11.40.

Innoviva (NASDAQ:INVA - Get Free Report) last released its earnings results on Wednesday, July 31st. The biotechnology company reported $0.68 EPS for the quarter. Innoviva had a return on equity of 33.26% and a net margin of 44.00%. The firm had revenue of $99.90 million for the quarter. Research analysts forecast that Innoviva, Inc. will post 0.5 earnings per share for the current fiscal year.

Innoviva Profile

Innoviva, Inc engages in the development and commercialization of pharmaceutical products in the United States and internationally. The company's products include RELVAR/BREO ELLIPTA, a once-daily combination medicine consisting of a LABA, vilanterol (VI), an inhaled corticosteroid (ICS), and fluticasone furoate; ANORO ELLIPTA, a once-daily medicine combining a long-acting muscarinic antagonist (LAMA) and umeclidinium bromide (UMEC) with a LABA, VI; GIAPREZA (angiotensin II), a vasoconstrictor to increase blood pressure in adults with septic or other distributive shock; XERAVA (eravacycline) for the treatment of complicated intra-abdominal infections in adults; and XACDURO, a beta lactamase inhibitor for the treatment of hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia.